scholarly journals Coagulopathy of liver disease does not increase the filter life during continuous renal replacement therapy

Critical Care ◽  
2009 ◽  
Vol 13 (Suppl 1) ◽  
pp. P267
Author(s):  
B Agarwal ◽  
S Shaw ◽  
M Hari
Keyword(s):  
Liver Disease ◽  
Renal Replacement Therapy ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Filter Life

scholarly journals Early mobilization on continuous renal replacement therapy is safe and may improve filter life

Critical Care ◽  
2014 ◽  
Vol 18 (4) ◽  
pp. R161 ◽  
Author(s):  
Yi Wang ◽  
Terry P Haines ◽  
Paul Ritchie ◽  
Craig Walker ◽  
Teri A Ansell ◽  
...  
Keyword(s):  
Renal Replacement Therapy ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Early Mobilization ◽  
Filter Life

Do anti-platelet drugs improve duration of continuous renal replacement therapy? A retrospective cohort study in cardiac ICU patients

2021 ◽  
pp. 039139882110312
Author(s):  
Vivek Gupta ◽  
Naved Aslam ◽  
Shibba Takkar Chhabra ◽  
Vikas Makkar ◽  
Bishav Mohan ◽  
...  
Keyword(s):  
Cohort Study ◽  
Renal Replacement Therapy ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
North India ◽  
Filter Life ◽  
Anti Platelet Drug ◽  
The Impact

Objective: The objective of this study was to investigate the impact of anti-platelet drug/s on duration of continuous renal replacement therapy (CRRT) in those patients where anti-coagulants were not used due to certain contraindications and in cases where patients were on anti-platelet drugs and were given anti-coagulant during CRRT. Method: This single-center, retrospective cohort study was conducted using the medical records patients treated with CRRT in the cardiac ICU of the inpatient urban facility, located in North India. Data was collected from only those patients who received CRRT for the duration of at least 12 h. Patient’s in NAC group were not on any anti-platelet/s and did not receive anti-coagulant during CRRT. AC and AP group patients received anti-coagulant alone or were already on anti-platelet/s and did not receive anti-coagulant respectively while ACAP group patients were on anti-platelet drug/s and also received anti-coagulant during CRRT. Result: Patients in AC, AP, or ACAP group showed significantly ( p < 0.001) higher CRRT filter life compared to NAC group. The median CRRT filter life was significantly higher in the ACAP group compared to AC ( p < 0.05) and AP ( p < 0.001) groups. Conclusion: This study indicates that systemic anti-platelet therapy can provide additional support in critical patients undergoing CRRT even with or without anti-coagulant therapy. However, the increase in CRRT filter life was more profound in patients who were on anti-platelet/s and also received anti-coagulant drug/s during CRRT.

scholarly journals A cost comparison of regional citrate versus low-dose systemic heparin anticoagulation in continuous renal replacement therapy

2019 ◽  
Vol 47 (3) ◽  
pp. 281-287 ◽  
Author(s):  
Chathuri U Dissanayake ◽  
Chrianna I Bharat ◽  
Brigit L Roberts ◽  
Matthew HR Anstey
Keyword(s):  
Renal Replacement Therapy ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Low Dose ◽  
Median Filter ◽  
Regional Citrate Anticoagulation ◽  
Secondary Outcome ◽  
Citrate Anticoagulation ◽  
Filter Life ◽  
Heparin Anticoagulation

We compared the cost of continuous renal replacement therapy (CRRT) in critically ill patients using two different anticoagulation strategies: regional citrate and low-dose systemic heparin in a single-centre, prospective observational study in an adult Australian tertiary intensive care unit (ICU). All patients receiving CRRT between October 2015 and May 2016 were included in the study. Costs were modelled using the number of filter sets, number of dialysis bags, amount of citrate, heparin and calcium replacement required, and cost of monitoring the anticoagulation. The primary outcome was cost associated with CRRT per patient per day. The secondary outcome was efficacy of CRRT. In total, 66 patients were commenced on dialysis that required anticoagulation. Twenty-four patients were commenced on regional citrate anticoagulation and 42 patients commenced on systemic low-dose heparin anticoagulation. Median filter life, though not statistically significant, was longer in the citrate group by 7.7 hours ( P=0.152), however the median cost of anticoagulation was AUD$317.91 higher in the citrate than the heparin group per patient per day ( P=0.0020). While regional citrate anticoagulation may prolong filter life, it is also more expensive than low-dose systemic heparin. Choice of anticoagulation in CRRT should include cost as one of the variables that clinicians consider.

Sign in / Sign up

Export Citation Format

Share Document